Dynavax Technologies | DVAX - Debt



Dynavax Technologies reported $260.51M in Debt for its fiscal quarter ending in March of 2025.


Debt Change Date
AbbVie USD 69.89B 2.74B Mar/2025
Adma Biologics USD 83.82M 11.49M Jun/2025
Amgen USD 56.2B 1.18B Jun/2025
AstraZeneca USD 32.84B 1.19B Jun/2025
Biogen USD 6.59B 296.8M Jun/2025
BioMarin Pharmaceutical USD 603.87M 8.22M Jun/2025
Bristol-Myers Squibb USD 50.93B 1.22B Jun/2025
Dynavax Technologies USD 260.51M 36.65M Mar/2025
Gilead Sciences USD 24.95B 6M Jun/2025
Glaxosmithkline GBP 17.35B 368M Jun/2025
Merck USD 34.84B 2.27B Mar/2025
Neurocrine Biosciences USD 439.1M 8.4M Jun/2025
Novartis USD 31.27B 12M Mar/2025
Pfizer USD 60.93B 1.18B Jun/2025
Regeneron Pharmaceuticals USD 2.71B 300K Jun/2025
Roche Holding CHF 34.44B 5.23B Jun/2024
Sarepta Therapeutics USD 1.35B 215.59M Jun/2025
TG Therapeutics USD 8.98M 235.45M Mar/2025
Vertex Pharmaceuticals USD 1.53B 121.7M Jun/2025